GLENMARK PHARMACEUTICALS LTD.

GLENMARK PHARMACEUTICALS LTD. - Updates

	< Back
15 Apr 2014
Glenmark Pharmaceuticals Ltd has informed BSE that the Company through its Swiss subsidiary has received USD 5 million as milestone payment from Sanofi on a collaboration of its VLA2 (alpha2-beta l) integrin monoclonal antibody. GBR 500 is a first-in-class therapeutic monoclonal antibody for chronic autoimmune disorders.<br/><br/>Glenmark has received from Sanofi already USD 50 Mn as an upfront payment in FY2011-12. Hence, the total amount received by Glenmark from Sanofi for its first in class VLA-2 monoclonal antibody is USD 55 million.
View all announcements for GLENMARK PHARMACEUTICALS LTD.	Source: BSE India

Stocks	Mutual Funds		Investment tracking
A-Z Gainers - Daily \| Weekly \| Monthly Losers - Daily \| Weekly \| Monthly Group-wise listing IPO \| Top IPOs Recent IPOs \| IPO News Similar Price band Most traded - By volumes Top 100 - By market capitalisation Latest Company Results Management Speaks Market News	Top 25 schemes High-risk, High-returns Medium-risk, Medium-returns Low-risk, Low-returns Gilt Funds Funds of Funds Special Funds Liquid Funds Dynamic Asset Allocation NFOs MF Selector	Equity - ELSS Equity - Index Funds Equity - Sector Funds Equity - Balance Fund Equity - Diversified Fund MF News Budget 2024	My Portfolio My Watch List If You Had Invested... Global Indicators Forex Converter Market Indices Sectoral Indices World Indices Market Astrology Advertise with us